(Q36719113)

15 August 2017

1 reference

title

Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots (English)

1 reference

idiopathic pulmonary fibrosis

15 August 2017

1 reference

1 reference

based on heuristic

inferred from title

pulmonary hypertension

1 reference

Steven D Nathan

1

1 reference

15 August 2017

Paul W Noble

series ordinal

2

1 reference

15 August 2017

Rubin M Tuder

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

25 January 2007

1 reference

American Journal of Respiratory and Critical Care Medicine

15 August 2017

published in

1 reference

15 August 2017

volume

175

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

875-880

1 reference

Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Idiopathic pulmonary fibrosis: new insights into pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

The clinical course of patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Advances in the diagnosis and treatment of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Angiogenic cytokines in patients with idiopathic interstitial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Endothelial dysfunction in pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Eicosanoids: mediators and therapeutic targets in fibrotic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Reversal of experimental pulmonary hypertension by PDGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Imatinib for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Brain natriuretic peptide is a prognostic parameter in chronic lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

Pulmonary Hypertension in Patients With Idiopathic Pulmonary Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200608-1153CC

10.1164/RCCM.200608-1153CC

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference